Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

COLLPLANT Aktie

>COLLPLANT Performance
1 Woche: -43,5%
1 Monat: +35,9%
3 Monate: -68,5%
6 Monate: -84,2%
1 Jahr: -80,9%
laufendes Jahr: -68,5%
>COLLPLANT Aktie
Name:  COLLPLANT BIOTECHNOLOGIES
Land:  Israel
Sektor:  Gesundheit
ISIN/ Wkn:  IL0004960188 / A1CY27
Symbol/ Ticker:  CPT (Frankfurt) / CLGN (NASDAQ)
Kürzel:  FRA:CPT, ETR:CPT, CPT:GR, NASDAQ:CLGN
Index:  -
Webseite:  https://collplant.com/
Profil:  CollPlant Biotechnologies Ltd. is a pioneering biomedical company that specializes in regenerative medicine and tissue engineering. At the heart of its offerings is the development of innovative human tissue products using plant-based recombinant col..
>Volltext..
Marktkapitalisierung:  6.6 Mio. EUR
Unternehmenswert:  3.91 Mio. EUR
Umsatz:  2.05 Mio. EUR
EBITDA:  -9.16 Mio. EUR
Nettogewinn:  -9.95 Mio. EUR
Gewinn je Aktie:  -0.81 EUR
Schulden:  2.47 Mio. EUR
Liquide Mittel:  5.15 Mio. EUR
Operativer Cashflow:  -8.65 Mio. EUR
Bargeldquote:  2.23
Umsatzwachstum:  360.39%
Gewinnwachstum:  30.83%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  COLLPLANT
Letzte Datenerhebung:  05.04.26
>COLLPLANT Kennzahlen
Aktien/ Unternehmen:
Aktien: 14.4 Mio. St.
Frei handelbar: 69.4%
Rückkaufquote: -43.18%
Mitarbeiter: 39
Umsatz/Mitarb.: 0.05 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: -
Bewertung:
KGV: -
KGV lG: -
KUV: 2.88
KBV: 1.11
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 26.32%
Gewinnmarge: -484.56%
Operative Marge: -484.31%
Managementeffizenz:
Gesamtkaprendite: -77.9%
Eigenkaprendite: -117.56%
>COLLPLANT Peer Group
Gesundheit, Medizinprodukte & -technik/ Implantate/ Wundpflege
 
26.03.26 - 13:45
CollPlant Biotechnologies Non-GAAP EPS of -$0.83, revenue of $2.37M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
26.03.26 - 13:33
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE (PR Newswire)
 
REHOVOT, Israel, March 26, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived rhCollagen for tissue regeneration and medical aesthetics, today......
24.03.26 - 21:09
CollPlant receives Nasdaq notice over minimum $1 bid price (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
24.03.26 - 21:03
CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement (PR Newswire)
 
REHOVOT, Israel, March 24, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced that on March......
11.03.26 - 13:03
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS (PR Newswire)
 
REHOVOT, Israel, March 11, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for medical aesthetics and tissue regeneration, today announced......
23.02.26 - 13:06
CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex (PR Newswire)
 
BioFlex Enables Rapid Formulation of Tunable rhCollagen Bioinks with Enhanced Tissue-Mimetic Performance BioFlex Expands CollPlant's Animal-Free Bioink Platform for Biopharma companies and Academic institutions Seeking Superior Biofunctionality and Reproducibility REHOVOT, Israel, Feb.......
17.02.26 - 13:01
CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments (PR Newswire)
 
Next-generation rhCollagen-based technology aims to restore facial structure and skin quality in patients experiencing volume depletion linked to GLP-1 weight-loss therapies REHOVOT, Israel, Feb. 17, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and......
05.02.26 - 14:03
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING (PR Newswire)
 
REHOVOT, Israel, Feb. 5, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today......
26.11.25 - 13:33
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE (PR Newswire)
 
Expansion of rhCollagen and BioInk raw material sales in North American territories expected through a new partnership with a U.S.-based logistics center scheduled to become operational this quarter and under new commercial leadership for this region Recent developments suggest......
27.10.25 - 12:03
CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada (PR Newswire)
 
-- New North American logistics center will provide expanded distribution for CollPlant's rhCollagen and BioInks as well as enable logistical efficiencies -- REHOVOT, Israel, Oct. 27, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine......
20.10.25 - 13:03
CollPlant′s rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology (PR Newswire)
 
A head-to-head study by Israel's Technion found that CollPlant's rhCollagen-based bioink, Collink.3D™, outperformed Matrigel®, a leading extracellular matrix, in supporting structured tissue formation. The findings suggest Collink.3D™ could offer a consistent, tunable, and animal-free......
16.10.25 - 13:03
First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant′s rhCollagen-Based BioInk (PR Newswire)
 
The bioprinted skin model is designed to serve as an alternative to animal testing for preclinical research. According to a scientific article published in the Archives of Dermatological Research, the model developed by Mayo Clinic researchers combines CollPlant's plant-derived......
30.09.25 - 17:24
Collplant-Aktie stürzt trotz Fortschritt bei Dermalfiller ab (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
30.09.25 - 13:06
CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler (PR Newswire)
 
CollPlant is now moving towards clinical trials and scaling and optimizing its manufacturing to ensure readiness for the upcoming clinical trials REHOVOT, Israel, Sept. 30, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company......
15.09.25 - 13:03
CollPlant Expands the Distribution of its VergenixSTR Product in Europe (PR Newswire)
 
REHOVOT, Israel, Sept. 15, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or 'CollPlant', a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics,......
02.09.25 - 13:03
CollPlant to Present at the 2025 International Conference on Biofabrication (PR Newswire)
 
REHOVOT, Israel, Sept. 2, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced its participation......
25.08.25 - 13:01
CollPlant to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference (PR Newswire)
 
REHOVOT, Israel, Aug. 25, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced that senior......
21.08.25 - 15:54
Analyst Expectations For CollPlant Biotechnologies€s Future (Benzinga)
 
Latest Ratings for CLGN DateFirmActionFromTo Feb 2021HC Wainwright & Co.MaintainsBuy May 2020HC Wainwright & Co.ReiteratesBuy Apr 2020HC Wainwright & Co.ReiteratesBuy View More Analyst Ratings for CLGN View the Latest Analyst Ratings read more...
20.08.25 - 13:18
CollPlant Biotechnologies Non-GAAP EPS of -$0.33, revenue of $2.23M misses by $0.31M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!